The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta-analysis
(2023)
Journal Article
Molica, S., Allsup, D., Polliack, A., & Giannarelli, D. (2023). The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta-analysis. European Journal of Haematology, 110(6), 774-777. https://doi.org/10.1111/ejh.13943
All Outputs (5)
The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta-analysis (2023)
Journal Article
Molica, S., Allsup, D., Polliack, A., & Giannarelli, D. (2023). The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta-analysis. European Journal of Haematology, https://doi.org/10.1111/ejh.13943
Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population (2023)
Journal Article
Molica, S., Shanafelt, T. D., Allsup, D., & Giannarelli, D. (2023). Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population. American Journal of Hematology, https://doi.org/10.1002/ajh.27182
Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia (2021)
Journal Article
Khan, S., Durairaj, S., Phumphukhieo, P., Holding, S., & Allsup, D. (2021). Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia. Leukemia & Lymphoma, 1-8. https://doi.org/10.1080/10428194.2021.1885662
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk (2014)
Journal Article
Sava, G. P., Speedy, H. E., Di Bernardo, M. C., Dyer, M. J., Holroyd, A., Sunter, N. J., …Houlston, R. S. (2015). Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 29(3), 748-751. https://doi.org/10.1038/leu.2014.311